Drugs of today (Barcelona, Spain : 1998)
Chernajovsky Y.
PMID: 12973439
Drugs Today (Barc). 1999 Apr-May;35(4):361-77. doi: 10.1358/dot.1999.35.4-5.552210.
Based on the beneficial effects of antibodies to tumor necrosis factor (TNF)-alpha and inhibitory cytokines, gene delivery of cytokines and cytokine inhibitors has been tried and shown to be of therapeutic benefit in the collagen-induced arthritis model in DBA/1...
Cite
Chernajovsky Y. Systemic gene therapy for arthritis. Drugs Today (Barc). 1999;35(4):361-77doi: 10.1358/dot.1999.35.4-5.552210.
Chernajovsky, Y. (1999). Systemic gene therapy for arthritis. Drugs of today (Barcelona, Spain : 1998), 35(4), 361-77. https://doi.org/10.1358/dot.1999.35.4-5.552210
Chernajovsky, Y. "Systemic gene therapy for arthritis." Drugs of today (Barcelona, Spain : 1998) vol. 35,4 (1999): 361-77. doi: https://doi.org/10.1358/dot.1999.35.4-5.552210
Chernajovsky Y. Systemic gene therapy for arthritis. Drugs Today (Barc). 1999 Apr-May;35(4):361-77. doi: 10.1358/dot.1999.35.4-5.552210. PMID: 12973439.
Copy
Download .nbib
Discovery medicine
Chernajovsky Y, Vessillier S, Adams G.
PMID: 20705016
Discov Med. 2004 Feb;4(20):30-2.
Extract: The holy grail of drug development is to design a magic bullet that will deliver a therapeutic agent only to the site of disease with minimal side effects. This is of great importance in particular when it refers...
Cite
Chernajovsky Y, Vessillier S, Adams G. Targeting therapeutic molecules to sites of disease. Discov Med. 2004;4(20):30-2
Chernajovsky, Y., Vessillier, S., & Adams, G. (2004). Targeting therapeutic molecules to sites of disease. Discovery medicine, 4(20), 30-2.
Chernajovsky, Yuti, et al. "Targeting therapeutic molecules to sites of disease." Discovery medicine vol. 4,20 (2004): 30-2.
Chernajovsky Y, Vessillier S, Adams G. Targeting therapeutic molecules to sites of disease. Discov Med. 2004 Feb;4(20):30-2. PMID: 20705016.
Copy
Download .nbib
